Search Results
19 protocol(s) meet the specified criteria
Phase I/IB, Open-Label, Multicenter Dose Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

Open-Label, Multicenter Phase IIA Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-Competent Oncolytic Adenovirus in Patients with Unresectable Metastatic Melanoma

Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

Multicenter Phase II, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

Phase IB/II, Multicenter, Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec

Randomized, Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) plus Yeast Cell Wall Particles (YCWP) plus Dendritic Cells (DC) Vaccine versus Unloaded YCWP plus DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

PV-10 versus Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Open-Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients with Advanced Malignancies

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Phase II Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death - 1 (Pd-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Multicenter Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)